Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > February 8, 2024
Daily News
February 8, 2024
- Mounjaro Logs 5.6 Billion Yen in Q3 YTD despite Curbed Shipments: Mitsubishi
February 8, 2024
- Kowa Snags Japan Rights to Nicox’s Eye Drop Asset for Glaucoma
February 8, 2024
- Kyowa Kirin Snares Japan Rights to BridgeBio’s Skeletal Dysplasias Drug
February 8, 2024
- Kyowa Kirin’s FY2023 Sales Up by 2-Digits, Operating Profit Hits Record High
February 8, 2024
- Generic Panel to Issue Report in Spring-Summer to Drive Manufacturing Efficiency towards Stable Supplies: Official
February 8, 2024
- Nick Eshkenazi to Join Astellas Top Management as Digital Chief
February 8, 2024
- Fluticasone Nasal Spray under Shipment Curbs Due to Quake, Middle East Unrest
February 8, 2024
- Quake-Hit Santen Plant to Fully Go Back Online in March
February 8, 2024
- Oncolys Forms Oncolytic Virus Sales Collab with Fujifilm in Japan
February 8, 2024
- Japan Ethical Drug Sales Up 0.8% in December: Crecon
February 8, 2024
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…